We currently have two FDA-approved drugs, sotorasib and adagrasib, that are used to treat advanced-stage NSCLC with KRAS G12C mutations. Watch the discussion with guest speakers Rosemary Conway (patient advocate who was diagnosed with KRAS G12D-positive NSCLC) and Dr. Kathryn Arbour, MD (thoracic oncologist, assistant attending physician at Memorial Sloan Kettering Cancer Center). Dr. Arbour received a 2020 LUNGevity Career Development Award and is studying how lung cancer cells become resistant to KRAS G12C-blocking drugs.
We have succeeded in targeting KRAS G12C mutations. Now what?
